Goldman Sachs analyst Matthew Sykes maintains GeneDx Hldgs (NASDAQ:WGS) with a Neutral and lowers the price target from $9 to $8.
Goldman Sachs Maintains Neutral on GeneDx Hldgs, Lowers Price Target to $8
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.